Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices

Abstract

Most new drugs that reach the market do not offer any significant therapeutic gain over existing products.[1][1],[2][2] Critics of the pharmaceutical industry have argued that these “me-too” drugs are a needless waste of resources. It can take hundreds of millions of dollars to develop them and